EP1030684A4 - Modified antibodies with enhanced ability to elicit an anti-idiotype response - Google Patents
Modified antibodies with enhanced ability to elicit an anti-idiotype responseInfo
- Publication number
- EP1030684A4 EP1030684A4 EP98958584A EP98958584A EP1030684A4 EP 1030684 A4 EP1030684 A4 EP 1030684A4 EP 98958584 A EP98958584 A EP 98958584A EP 98958584 A EP98958584 A EP 98958584A EP 1030684 A4 EP1030684 A4 EP 1030684A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- elicit
- modified antibodies
- enhanced ability
- idiotype response
- idiotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003302 anti-idiotype Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6571697P | 1997-11-14 | 1997-11-14 | |
US65716P | 1997-11-14 | ||
US8140398P | 1998-04-10 | 1998-04-10 | |
US81403P | 1998-04-10 | ||
PCT/US1998/024303 WO1999025379A1 (en) | 1997-11-14 | 1998-11-13 | Modified antibodies with enhanced ability to elicit an anti-idiotype response |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1030684A1 EP1030684A1 (en) | 2000-08-30 |
EP1030684A4 true EP1030684A4 (en) | 2004-09-15 |
Family
ID=26745908
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98958584A Withdrawn EP1030684A4 (en) | 1997-11-14 | 1998-11-13 | Modified antibodies with enhanced ability to elicit an anti-idiotype response |
EP98958583A Withdrawn EP1032420A4 (en) | 1997-11-14 | 1998-11-13 | Immunoglobulin molecules having a synthetic variable region and modified specificity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98958583A Withdrawn EP1032420A4 (en) | 1997-11-14 | 1998-11-13 | Immunoglobulin molecules having a synthetic variable region and modified specificity |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP1030684A4 (en) |
JP (2) | JP2002507544A (en) |
KR (2) | KR20010015817A (en) |
CN (2) | CN1327388A (en) |
AU (2) | AU763029B2 (en) |
BR (2) | BR9815289A (en) |
CA (2) | CA2310269A1 (en) |
IL (2) | IL136114A0 (en) |
WO (2) | WO1999025379A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2350917A1 (en) * | 1998-11-13 | 2000-05-25 | Euro-Celtique, S.A. | Contraceptive antibody vaccines |
DK1092779T3 (en) * | 1999-10-11 | 2010-02-15 | Pasteur Institut | Lentivirus virus vectors for the preparation of immunotherapeutic preparations |
AU2001261628A1 (en) * | 2000-05-16 | 2001-11-26 | Euroceltique S.A. | Cd28 synthebody for the modulation of immune responses |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
EP1498429A3 (en) * | 2000-12-05 | 2005-08-03 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
GB0103174D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Plc | Novel method of treatment |
WO2002078613A2 (en) * | 2001-04-02 | 2002-10-10 | Purdue Pharma L.P. | Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response |
WO2003063768A2 (en) * | 2001-10-25 | 2003-08-07 | Euro-Celtique S.A. | Compositions and methods directed to anthrax toxin |
ES2301794T3 (en) * | 2002-04-09 | 2008-07-01 | The Curators Of The University Of Missouri | TREATMENT OF TYPE 1 DIABETES, BEFORE AND AFTER THE EXPRESSION OF PREDISPOSITION MARKERS. |
NZ536475A (en) | 2002-05-24 | 2008-06-30 | Schering Corp | Neutralizing human anti-igfr antibody |
AR040778A1 (en) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY). |
NZ538996A (en) | 2002-10-31 | 2008-04-30 | Genentech Inc | Methods and compositions for increasing antibody production |
GB0306309D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
WO2005021595A1 (en) * | 2003-08-28 | 2005-03-10 | Euro-Celtique S.A. | Methods of antibody engineering using antibody display rules |
EP1694850B1 (en) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmid system for multigene expression |
TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
CA2558813A1 (en) * | 2004-03-09 | 2005-09-15 | Kyoto University | Pharmaceutical composition comprising cxcr3 inhibitor |
ATE493442T1 (en) | 2004-12-03 | 2011-01-15 | Schering Corp | BIOLOGICAL MARKERS FOR PRE-SELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY |
ZA200901165B (en) * | 2006-08-28 | 2010-06-30 | Kyowa Hakko Kirin Co Ltd | Antagonistic human light-specific human monoclonal antibodies |
GB0706070D0 (en) | 2007-03-28 | 2007-05-09 | Scancell Ltd | Nucleic acids |
NZ587305A (en) * | 2008-03-12 | 2012-05-25 | Imclone Llc | Anti-tyrosinase-realted protein-1 (TYRP1) antibodies |
JP5925116B2 (en) * | 2009-04-29 | 2016-05-25 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | ERG monoclonal antibody |
CN102816240B (en) * | 2011-03-08 | 2014-02-12 | 中国人民解放军第三军医大学第二附属医院 | Fusion protein and fusion protein expression vector thereof |
WO2012166712A1 (en) * | 2011-05-27 | 2012-12-06 | Fox Chase Cancer Center | Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies |
US9902760B2 (en) * | 2011-11-23 | 2018-02-27 | Bioven 3 Limited | Recombinant proteins and their therapeutic uses |
JP5437525B1 (en) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | Tyrosine derivative and method for producing tyrosine derivative |
CN105705522B (en) * | 2013-05-14 | 2020-09-15 | 上海亨臻实业有限公司 | Epitope vaccine aiming at low-immunogenicity protein and preparation method and application thereof |
CN103275914B (en) * | 2013-06-03 | 2015-04-01 | 中国人民解放军军事医学科学院微生物流行病研究所 | Bacterial ghost presenting protective antigens and application thereof |
CN105263953B (en) * | 2014-01-15 | 2020-01-07 | 勃林格殷格翰动物保健美国有限公司 | Porcine parvovirus 5A, methods of use, and vaccines |
JP6705755B2 (en) * | 2014-05-19 | 2020-06-03 | バロ セラピューティクス オイValo Therapeutics Oy | Modified adenovirus for cancer vaccine development |
CN105693859B (en) * | 2016-03-22 | 2019-06-21 | 苏州莱泰生物科技有限公司 | Anti-human G2A monoclonal antibody and the kit for detecting human macrophage G2A expression quantity |
CN111978382B (en) * | 2020-09-03 | 2022-03-04 | 吉林大学第一医院 | Preparation method and application of recombinant protein of Sporothrix globosum Gp70 |
CN112646029B (en) * | 2020-12-30 | 2022-07-29 | 深圳清华大学研究院 | Antibody of mature brain-derived neurotrophic factor, application thereof and diagnostic kit |
CN115856296B (en) * | 2022-12-16 | 2023-07-25 | 华北理工大学 | Monoclonal antibody for resisting shigella and application thereof in detection |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011509A2 (en) * | 1992-11-16 | 1994-05-26 | Cancer Research Fund Of Contra Costa | Peptides and anti-sense peptides with broad neoplastic specificity |
WO1996008514A1 (en) * | 1994-09-12 | 1996-03-21 | Tsang Kwong Y | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0460076B1 (en) * | 1989-02-24 | 1995-11-29 | The Regents Of The University Of California | Genetically engineered immunoglobulins |
GB9019553D0 (en) * | 1990-09-07 | 1990-10-24 | Unilever Plc | Specific binding agents |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
WO1994014848A1 (en) * | 1992-12-24 | 1994-07-07 | The Regents Of The University Of California | Genetically engineered immunoglobulins |
WO1994014847A1 (en) * | 1992-12-24 | 1994-07-07 | The Regents Of The University Of California | Genetically engineered immunoglobulins |
US5476784A (en) * | 1993-04-06 | 1995-12-19 | Rice; Peter A. | Gonococcal anti-idiotypic antibodies and methods and compositions using them |
US5653977A (en) * | 1993-09-09 | 1997-08-05 | Uab Research Foundation | Anti-idiotypic antibody that mimics the GD2 antigen |
US5624904A (en) * | 1993-11-17 | 1997-04-29 | Massachusetts Institute Of Technology | Method for treating gram positive septicemia |
-
1998
- 1998-11-13 BR BR9815289-0A patent/BR9815289A/en not_active IP Right Cessation
- 1998-11-13 AU AU14597/99A patent/AU763029B2/en not_active Ceased
- 1998-11-13 CA CA002310269A patent/CA2310269A1/en not_active Abandoned
- 1998-11-13 IL IL13611498A patent/IL136114A0/en unknown
- 1998-11-13 KR KR1020007005263A patent/KR20010015817A/en not_active Application Discontinuation
- 1998-11-13 WO PCT/US1998/024303 patent/WO1999025379A1/en not_active Application Discontinuation
- 1998-11-13 EP EP98958584A patent/EP1030684A4/en not_active Withdrawn
- 1998-11-13 WO PCT/US1998/024302 patent/WO1999025378A1/en not_active Application Discontinuation
- 1998-11-13 JP JP2000520812A patent/JP2002507544A/en active Pending
- 1998-11-13 CA CA002309990A patent/CA2309990A1/en not_active Abandoned
- 1998-11-13 CN CN98813119A patent/CN1327388A/en active Pending
- 1998-11-13 BR BR9815580-6A patent/BR9815580A/en not_active IP Right Cessation
- 1998-11-13 IL IL13611398A patent/IL136113A0/en unknown
- 1998-11-13 KR KR1020007005264A patent/KR20010015818A/en not_active Application Discontinuation
- 1998-11-13 EP EP98958583A patent/EP1032420A4/en not_active Withdrawn
- 1998-11-13 CN CN98813117A patent/CN1294517A/en active Pending
- 1998-11-13 JP JP2000520811A patent/JP2001526021A/en active Pending
-
2003
- 2003-10-10 AU AU2003252902A patent/AU2003252902A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011509A2 (en) * | 1992-11-16 | 1994-05-26 | Cancer Research Fund Of Contra Costa | Peptides and anti-sense peptides with broad neoplastic specificity |
WO1996008514A1 (en) * | 1994-09-12 | 1996-03-21 | Tsang Kwong Y | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
Non-Patent Citations (5)
Title |
---|
"Patent evaluation: Site-specific structural modification of monoclonal antibodies for therapeutic application.", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, no. 2, 2000, pages 251 - 253, XP002288085 * |
H. HOLZMANN ET AL.: "Assessment of the antigenic structure of tick-borne encephalitis virus by the use of synthetic peptides.", JOURNAL OF GENERAL VIROLOGY, vol. 74, no. 9, September 1993 (1993-09-01), pages 2031 - 2035, XP002287488 * |
K. PROBA ET AL.: "A natural antibody missing a cysteine in VH: Consequences for thermodynamic stability and folding.", JOURNAL OF MOLECULAR BIOLOGY, vol. 265, no. 2, 17 January 1997 (1997-01-17), pages 161 - 172, XP004462317 * |
L. REIDL ET AL.: "Structural basis of a conserved idiotope expressed by an autoreactive human B cell lymphoma. Evidence that a VH CDR3 mutation alters idiotypy and specificity.", THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 10, 15 November 1991 (1991-11-15), BALTIMORE, MD, USA, pages 3623 - 3631, XP002287487 * |
See also references of WO9925379A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1032420A1 (en) | 2000-09-06 |
IL136114A0 (en) | 2001-05-20 |
AU1459899A (en) | 1999-06-07 |
AU737457B2 (en) | 2001-08-23 |
BR9815289A (en) | 2001-12-26 |
EP1032420A4 (en) | 2004-09-15 |
JP2001526021A (en) | 2001-12-18 |
WO1999025379A1 (en) | 1999-05-27 |
WO1999025378A9 (en) | 1999-08-12 |
AU1459799A (en) | 1999-06-07 |
CN1294517A (en) | 2001-05-09 |
BR9815580A (en) | 2002-01-29 |
CA2310269A1 (en) | 1999-05-27 |
IL136113A0 (en) | 2001-05-20 |
EP1030684A1 (en) | 2000-08-30 |
AU2003252902A1 (en) | 2003-11-06 |
AU763029B2 (en) | 2003-07-10 |
JP2002507544A (en) | 2002-03-12 |
WO1999025378A1 (en) | 1999-05-27 |
KR20010015818A (en) | 2001-02-26 |
CA2309990A1 (en) | 1999-05-27 |
KR20010015817A (en) | 2001-02-26 |
CN1327388A (en) | 2001-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL136113A0 (en) | Modified antibodies with enhanced ability to elicit an anti-idiotype response | |
IL136335A0 (en) | Monoclonal human natural antibodies | |
GB9701669D0 (en) | Improvements to structure | |
EP0973537A4 (en) | Cocaethylene immunogens and antibodies | |
EP0991321A4 (en) | Tolerance to natural antibody antigens | |
ZA9948B (en) | Modified antibodies with enhanced ability to elicit an anti-idiotype response. | |
GB9723062D0 (en) | Improvements relating to antibodies and libraries thereof | |
GB9726147D0 (en) | Antigens | |
TW312301U (en) | Improved structure of earmask | |
TW319017U (en) | Improved structure of mousetraps | |
TW317278U (en) | Improved structure of fastener | |
TW341916U (en) | Improved structure of date chops | |
GB9703276D0 (en) | Materials and methods relating to the protection of useful immune cells | |
TW371836U (en) | Structure of the multi-functional heater | |
TW323759U (en) | Improved structure of pipeline connecting set | |
GB9701782D0 (en) | Improvements relating to covering materials and methods | |
HK1038687A1 (en) | Antibodies to truncated vegf-d and uses thereof | |
GB9722214D0 (en) | Improvements in and relating to the manufacture of fire surrounds | |
TW380680U (en) | Improved structure of the revolving-horse-lamp | |
CA80435S (en) | Sun shelter | |
TW320050U (en) | Improved structure of pacifier clip | |
TW323471U (en) | Improved structure of hairclip | |
TW317745U (en) | Improved structure of mini-duster | |
TW320865U (en) | Improved structure of shoe-embossing device | |
TW387335U (en) | Improvement of net structure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000609 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040730 |
|
17Q | First examination report despatched |
Effective date: 20060622 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060515 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1032201 Country of ref document: HK |